Table 1

Baseline demographics (effectiveness set; n=893)

UST (n=438)TNFi (n=455)
Age years51.0 (12.5) (49.9; 52.2)48.5 (12.5) (47.3; 49.7)
Female, n (%)246 (56.2) (51.4; 60.9)248 (54.5) (49.8; 59.1)
BMI, kg/m2 28.6 (6.2) (27.9; 29.2)27.7 (5.3) (27.2; 28.2)
Disease duration since initial diagnosis, years7.5 (8.1) (6.7; 8.3)6.2 (6.6) (5.6; 6.9)
Line of bDMARD treatment, n (%)
 First-line197 (45.0) (40.3; 49.8)251 (55.2) (50.5; 59.8)
 Second-line151 (34.5) (30.0; 39.1)149 (32.7) (28.4; 37.3)
 Third-line90 (20.5) (16.9; 24.6)55 (12.1) (9.2; 15.4)
csDMARD exposure, n (%)
 Previous exposure384 (87.7) (84.2; 90.6)421 (92.5) (89.7; 94.8)
 Ongoing exposure at baseline173 (39.5) (34.9; 44.2)251 (55.2) (50.5; 59.8)
 MTX exposure ongoing at baseline131 (29.9) (25.7; 34.4)191 (42.0) (37.4; 46.7)
 Weekly MTX dose, mg15.3 (5.5) (14.3; 16.3)15.0 (4.6) (14.3; 15.7)
Other treatments exposure ongoing at baseline, n (%)
 NSAIDs240 (54.8) (50.0; 59.5)313 (68.8) (64.3; 73.0)
 Glucocorticosteroids143 (32.6) (28.3; 37.3)156 (34.3) (29.9; 38.8)
Comorbidities present, n (%)301 (68.7) (64.1; 73.0)277 (60.9) (56.2; 65.4)
 Cardiovascular disease/
 metabolic syndrome*
184 (42.0) (37.3; 46.8)162 (35.6) (31.2; 40.2)
 Anxiety or panic disorders18 (4.1) (2.5; 6.4)18 (4.0) (2.4; 6.2)
 Depression40 (9.1) (6.6; 12.2)29 (6.4) (4.3; 9.0)
 GI disease or medical history of IBD55 (12.6) (9.6; 16.0)49 (10.8) (8.1; 14.0)
 FiRST score suggestive of chronic widespread pain (scores ≥5)163 (39.0) (34.3; 43.9)126 (29.4) (25.2; 34.0)
  • Data are mean (SD) (95% CI of the mean) unless otherwise stated; % is that of available data. Variables in bold indicate non-overlapping 95% CI.

  • *Hypertension, myocardial infarction, congestive heart failure, stroke or transient ischaemic attack, peripheral vascular disease, hyperlipidaemia, type 1 or type 2 diabetes or angina pectoris.

  • bDMARD, biologic disease-modifying antirheumatic drug; BMI, body mass index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; FiRST, Fibromyalgia Rapid Screening Tool; GI, gastrointestinal; IBD, inflammatory bowel disease; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab.